特别是,HER2-low 乳腺癌与 pCR 率最低相关,其次是 HER2-0 和 HER2 阳性肿瘤(pCR率 HER2-low-positive vs. HER2-0 vs. HER2-positive:分别为21.4% ,33.6% 和45.9%,p < 0.001)。 新辅助治疗后,HER2表达的不稳定性 整体而言,35.3% ...
11. Miglietta F et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer,2022,8(1):66-72. 12.Denkert C et al. Clinical and molecular characteristics of HER2-low-positive brea...
研究团队对7例TNBC患者(HER2-negative vs HER2-low,4 vs 3)的36168个细胞进行单细胞RNA测序(scRNA-seq),以进一步探索两种不同表型的TNBC之间肿瘤生物学特性的差异。结果显示: 与HER2-low TNBC相比,HER2-negativeative TNBC内皮细胞(1.8%对8.1%,P < 0.05)和成纤维细胞(1.8%对8.1%,P < 0.05)占比较...
尽管抗HER2治疗极大改善了HER2阳性乳腺癌患者的预后,但仍有很大一部分HER2低表达患者并未从抗HER2治疗中显著获益。为了进一步描述这种新的乳腺癌亚型的特征,2021年7月9日,柳叶刀肿瘤学分册(Lancet Oncol.)发表的一项研究比较了HER2低表达(HER2-low-positive)和HER2零表达(HER2-zero)乳腺癌的临床和分子特征,包括对新辅...
而且,在HR阳性亚组中发现的HER2-low肿瘤患者比例高于HR阴性亚组(46%vs.35.3%,p<0.001),提示HR表达在HER2-low肿瘤中的重要作用。此外,我们观察到大多数(73.5%)HER2-low患者中的HER2 IHC 1+亚组占比,与HR状态无关(HR阳性亚组33.0%vs.HR阴性亚组28.1%,p=0.75),这与既往结果一致[2]。HER2-low和HER2-0...
研究团队对7例TNBC患者(HER2-negative vs HER2-low,4 vs 3)的36168个细胞进行单细胞RNA测序(scRNA-seq),以进一步探索两种不同表型的TNBC之间肿瘤生物学特性的差异。结果显示: 与HER2-low TNBC相比,HER2-negativeative TNBC内皮细胞(1.8%对8.1%,P < 0.05)和成纤维细胞(1.8%对8.1%,P < 0.05)占比较...
[3] Gilcrease MZ, Woodward WA, Nicolas MM, et al. Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer. Am J Surg Pathol. 2009 May;33(5):759-767. [4] Rossi V, Sarotto I, Maggiorotto F et al (2012) Moderate immunohistochemical expression...
根据PR状态组合，将所有患者分为4个亚组：ER neg或ER low/PR-、ER neg或ER low/PR+、ER high/PR-和ER high/PR+。■ 研究终点和定义 本研究旨在分析不同HR状态的HER2阳性患者的临床病理学特征、pCR率和生存结局。此外，本研究旨在探索预测pCR率、DFS和OS的因素。主要研究终点是pCR率，次要终点包括DFS和OS。
在HER2 ultralow的病理染色实践中，已经积累了丰富的临床和科研经验，全方位助力客户临床转化医学研究。参考文献 [1] Curigliano G, et al. Trastuzumabderuxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients(pts) with hormone receptor-positive (HR+), human epidermal growth factor...
[1] Curigliano G, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy ...